Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | ITK | Q08881 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.36 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 8/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.34 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9467972 | 0.82 | MAPT (0.43) | EGFRITKPOLBDUSP3PTPN5 | |
| SCHEMBL1670862 | 0.80 | LMNA (0.41) | EGFRITKPOLBDUSP3PTPN5 | |
| SCHEMBL13185172 | 0.78 | POLB (0.45) | EGFRITKPOLBDUSP3PTPN5 | |
| SCHEMBL1670175 | 0.74 | CYP2D6 (0.39) | MAPTKMT2ACYP2D6 | |
| SCHEMBL1670233 | 0.73 | SLC5A2 (0.42) | POLBMAPTLMNACYP2D6HTT | |
| SCHEMBL13606320 | 0.71 | MAPT (0.55) | POLBMAPTTP53LMNAKMT2A | |
| SCHEMBL13165272 | 0.69 | ALDH1A1 (0.45) | EGFRITKPOLBTDP1MAPT | |
| SCHEMBL1672720 | 0.68 | SLC5A2 (0.38) | POLB | |
| SCHEMBL20927033 | 0.68 | MAPT (0.42) | EGFRITKPOLBDUSP3PTPN5 | |
| SCHEMBL1670973 | 0.68 | NOTUM (0.65) | POLBMAPTTP53LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49080-E1 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2022-05-24 | — | — | US | disclosed |
| US-9895389-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2018-02-20 | — | — | US | disclosed |
| US-20170042925-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2017-02-16 | — | — | US | disclosed |
| EP-2491029-B1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2016-02-10 | — | — | EP | disclosed |
| US-20150141354-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2015-05-21 | — | — | US | disclosed |
| US-20140274921-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-8828951-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2014-09-09 | — | — | US | disclosed |
| US-8466114-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2013-06-18 | — | — | US | disclosed |
| US-20130017993-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2013-01-17 | — | — | US | disclosed |
| EP-2491029-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2012-08-29 | — | — | EP | disclosed |
| US-20120178680-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2012-07-12 | — | — | US | disclosed |
| US-8163704-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| US-20110171159-A1 | Glycoside Derivatives and Uses Thereof | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| WO-2011048112-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170042925-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | EGFR 2970/4885ITK 1493/4885POLB 4847/4885 |
| US-20120178680-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | EGFR 2970/4885ITK 1493/4885POLB 4847/4885 |
| US-20150141354-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | EGFR 2970/4885ITK 1493/4885POLB 4847/4885 |
| US-20130017993-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | EGFR 2970/4885ITK 1493/4885POLB 4847/4885 |
| US-20110171159-A1 | Glycoside Derivatives and Uses Thereof | SLC5A1, SLC5A2, SLC2A1 | EGFR 2970/4885ITK 1493/4885POLB 4847/4885 |
| US-20140274921-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | EGFR 2970/4885ITK 1493/4885POLB 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.